Specific identification tests are not conducted on components that have been accepted based on the supplier's report of analysis.
Inspection Record
Tripak Pharmaceuticals Pty Ltd. — FDA 483 Findings
Inspectors Nibin VargheseThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
There is no written testing program designed to assess the stability characteristics of drug products.
The quality control unit lacks the responsibility and authority to approve, reject all drug products.
Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
Laboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, drug product closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Guangxi Yulin Pharmaceutical Group Co. Ltd.2025-03-21 · US FDASimilar to finding 2 There is no written testing program designed to assess the stability characteristics of drug products.
- Glenmark Pharmaceuticals Inc USA2022-05-19 · US FDASimilar to finding 4 Time limits are not established when appropriate for the completion of each production phase to assure the quality of the drug product.
- Precision Pharmacy Center LLC2016-06-17 · US FDASimilar to finding 2 There is no written testing program designed-to assess the stability characteristics of drug products.
- Jiangsu Intco Medical Products Co., Ltd2023-11-17 · US FDASimilar to finding 2 There is no written testing program designed to assess the stability characteristics of drug products.
- Bello Bio LLC2025-12-16 · US FDASimilar to finding 2 There is no written testing program designed to assess the stability characteristics of drug products.
A record as of the US FDA document published on 2026-11-13. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.